Prevention of Macrovascular Disease in Patients with Diabetes Mellitus: Opportunities for Intervention

American Journal of Medicine

Volumn 120, Issue 9 SUPPL. 2, 2007, Pages

  Mazzone, Theodore ^a  

^a Section of Endocrinology Diabetes and Metabolism   (United States)

Author keywords

Atherosclerosis; Clinical trial; Macrovascular disease; Pioglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TROGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MECHANISM; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; UNITED STATES; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; THIAZOLIDINEDIONES;

EID: 34548382484     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.005     Document Type: Article

References (31)

1. Thom T., Haase N., Rosamond W., et al., American Heart Association Statistics Committee and Stroke Statistics Committee. Heart disease and stroke statistics-2006 update: a report from the AHA Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Haffner S.M., Lehto S., Ronnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
3. Libby P., and Plutzky J. Diabetic macrovasular disease: the glucose paradox?. Circulation 106 (2002) 2760-2763
4. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
6. Turnbull F., Neal B., Algert C., et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
8. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
9. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
10. Keating G.M., and Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 62 (2002) 1909-1944
11. Keech A., Simes R.J., Barter P., et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
12. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet 366 (2005) 1829-1831
13. Prisant L.M. Clinical trials and lipid guidelines for type II diabetes. J Clin Pharmacol 44 (2004) 423-430
14. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
15. Fonseca V., Desouza C., Asnani S., and Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
16. Pfutzner P., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Cardiol 45 (2005) 1925-1931
17. Kunhiraman B.P., Jawa A., and Fonseca V.A. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am 34 (2005) 117-135
18. Collins A.R., Meehan W.P., Kintscher U., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 365-371
19. Chen Z., Ishibashi S., Perrey S., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21 (2001) 372-377
20. Li A.C., Brown K.K., Silverstre M.J., et al. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
21. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR-α, β/δ, and γ. J Clin Invest 114 (2004) 1564-1576
22. Dormandy J.A., Charbonnel B., Eckland D.J., et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
23. Erdman E., Dormandy J.A., Charbonnel B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49 (2007) 1772-1780
24. Wilcox R.G., Bouser M.-.G., and Dormandy J. The effects of pioglitazone in patients with or without a history of stroke (≥6 months prior to randomization)-a pre-specified subgroup analysis of PROactive (PROspective pioglitAzone Clinical Trial In Macrovascular Events). [slide presentation] (2006). http://www.proactive-results.com/ppt/Stroke%20WCC%20slidesFINAL.ppt Presented at the World Congress of Cardiology; September 3, Barcelona, Spain. Available at: http://www.proactive-results.com/ppt/Stroke%20WCC%20slidesFINAL.ppt. Accessed January 17, 2007.
25. Crouse J.R. Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art. J Lipid Res 47 (2006) 1677-1699
26. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
27. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 296 (2006) 2572-2581
28. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med 356 (2007) 2457-2471
29. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48 (2005) 1726-1735
30. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
31. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. [published correction appears in Lancet. 2006;368:1770]. Lancet 368 (2006) 1096-1105